Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Seeking Alpha • Feb 18, 2026

Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?

Here is how Allogene Therapeutics (ALLO) and McKesson (MCK) have performed compared to their sector so far this year.

Zacks Investment Research • Feb 11, 2026

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in the first quarter of 2026.

GlobeNewsWire • Feb 5, 2026

Rapid Innovation is Reshaping Oncology: Stocks in Focus

Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.

Zacks Investment Research • Feb 5, 2026

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Here is how Allogene Therapeutics (ALLO) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.

Zacks Investment Research • Jan 26, 2026

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today outlined 2026 as a program-defining year for allogeneic CAR T, with multiple first-half clinical readouts expected to test, and potentially validate, whether off-the-shelf CAR T can be delivered at biologic-like scale, in real-world settings, across oncology and autoimmune disease.

GlobeNewsWire • Jan 8, 2026

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on Track SOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today noted the favorable outcome for Servier in its arbitration with Cellectis (Euronext Growth: ALCLS –  NASDAQ: CLLS) as it relates to cemacabtagene ansegedleucel (cema-cel).

GlobeNewsWire • Dec 15, 2025

Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript

Allogene Therapeutics, Inc. ( ALLO ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - Executive VP of Research & Development and Chief Medical Officer Geoffrey Parker - Executive VP & CFO Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Tyler Van Buren - TD Cowen, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Samantha Corwin - William Blair & Company L.L.C.

Seeking Alpha • Nov 7, 2025

Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales

ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.

Zacks Investment Research • Nov 7, 2025

Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T

Allogene Therapeutics, Inc. is downgraded from Strong Buy to Hold due to setbacks in its pivotal phase 2 ALPHA3 trial. ALLO's cema-cel for Large B-Cell Lymphoma remains on track for a key futility analysis in H1 2026, but must proceed without ALLO-647. ALLO-316 showed a 31% response rate in advanced RCC patients with CD70+ TPS ≥50%, but future studies will require this narrow focus.

Seeking Alpha • Nov 7, 2025